^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MAPK1 overexpression

i
Other names: MAPK1, ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2, Mitogen-activated protein kinase 1
Entrez ID:
Related biomarkers:
over1year
Microarray Analysis of Visceral Adipose Tissue in Obese Women Reveals Common Crossroads Among Inflammation, Metabolism, Addictive Behaviors, and Cancer: AKT3 and MAPK1 Cross Point in Obesity. (PubMed, J Obes)
VAT confers a complex and blended pathogenic transcriptomic profile in obese patients, where abnormal processes are mainly controlled by activating intracellular signaling pathways that exhibit a high degree of redundancy. Identifying shared cross points between those pathways could allow specific targeting treatments to exert a widespread effect over multiple pathogenic processes.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • MAPK1 (Mitogen-activated protein kinase 1) • AKT3 (V-akt murine thymoma viral oncogene homolog 3)
|
MAPK1 overexpression
over1year
MicroRNA-34a negatively regulates Netrin1 and mediates MEK/ERK pathway to regulate chemosensitivity of gastric cancer cells. (PubMed, Discov Oncol)
miR-34a targets and negatively regulates Netrin1 to mediate the proliferation, apoptosis, apoptosis, migration, and invasion of drug-resistant gastric cancer cells via the MEK/ERK pathway, and change the chemosensitivity in GC cells. miR-34a/Netrin1/MEK/ERK axis may serve as a novel therapeutic target for chemoresistance in GC, it is of great significance for overcoming drug resistance and developing new therapeutic strategies for GC.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CDH1 (Cadherin 1) • MIR34A (MicroRNA 34a-5p) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen) • NTN1 (Netrin 1)
|
CDH1 expression • MAPK1 overexpression • miR-34a expression
|
cisplatin
over2years
p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer. (PubMed, Head Neck Pathol)
High p-mTOR expression predicts and high p-ERK expression tends to predict worse treatment outcome in HPV negative HNSCC patients treated with chemoradiation, providing additional evidence that these markers are candidate prognostic biomarkers for survival in this patient population. Also this study shows that the use of HNSCC organoids for biomarker research has potential. The role of PTEN expression as prognostic biomarker remains unclear, as consistent evidence on its prognostic and predictive value is lacking.
Journal • Biopsy
|
PTEN (Phosphatase and tensin homolog) • MAPK1 (Mitogen-activated protein kinase 1)
|
PTEN expression • MAPK1 overexpression
|
Erbitux (cetuximab) • cisplatin • carboplatin • everolimus
over2years
Phosphorylated MAPK11 promotes the progression of clear cell renal cell carcinoma by maintaining RUNX2 protein abundance. (PubMed, J Cell Mol Med)
The high expression of RUNX2 could neutralize the functional degradation in MAPK11. And the outcomes of the study suggest that the P-MAPK11/RUNX2 axis may be used as a potential therapeutic target of ccRCC.
Journal
|
MAPK1 (Mitogen-activated protein kinase 1) • MAPK11 (Mitogen-Activated Protein Kinase 11) • RUNX2 (RUNX Family Transcription Factor 2)
|
MAPK1 overexpression
over2years
TRIM26 inhibited osteosarcoma progression through destabilizing RACK1 and thus inactivation of MEK/ERK signaling. (PubMed, Cell Death Dis)
Further, a series of gain- and loss-of-function experiments showed that decreased malignant behaviors including cell proliferation and invasion in TRIM26-upregulated cells were reversed when RACK1 was overexpressed, whereas RACK1 knockdown diminished the increased malignant phenotypes in TRIM26-silenced osteosarcoma cells. In conclusion, our study indicated that TRIM26 inhibited osteosarcoma progression via promoting proteasomal degradation of RACK1, thereby resulting in inactivation of MEK/ERK signaling, and impeding the EMT process.
Journal
|
MAP2K1 (Mitogen-activated protein kinase kinase 1) • RACK1 (Receptor For Activated C Kinase 1)
|
MAPK1 overexpression • MAP2K1 overexpression
over2years
The inhibitor of MyoD Family A (I-MFA) regulates megakaryocyte lineage commitment and terminal differentiation. (PubMed, Blood Cells Mol Dis)
Overexpression of I-MFA promoted MK differentiation. These results suggest I-MFA plays a cell-intrinsic role in the response to differentiation signals, an effect that can be explored in the context of hematological cancers or other blood proliferative disorders.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
MAPK1 overexpression
almost3years
FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation. (PubMed, J Exp Clin Cancer Res)
This study provided evidence that FBXW7 loss of function promoted ESCC via MAP4 overexpression and ERK phosphorylation, and this novel FBXW7/MAP4/ERK axis may be an efficient target for ESCC treatment.
Journal
|
FBXW7 (F-Box And WD Repeat Domain Containing 7) • CHEK1 (Checkpoint kinase 1) • MAP4 (Microtubule Associated Protein 4) • MMP3 (Matrix metallopeptidase 3)
|
MAPK1 overexpression
|
Avastin (bevacizumab) • MK-8353
almost3years
Apolipoprotein E enhances migration of endometrial cancer cells byactivating the ERK/MMP9 signaling pathway (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
APOE is highly expressed in endometrial cancer tissues to promote cancer cell migration by enhancing ERK phosphorylation and MMP9 expression.
Journal
|
MMP9 (Matrix metallopeptidase 9) • APOE (Apolipoprotein E)
|
MAPK1 overexpression
almost3years
Has_circ_0071803 promotes colorectal cancer progression by regulating miR-330-5p/MAPK signaling pathway. (PubMed, Histol Histopathol)
The suppression of cell activities by circ_0071803 knockdown were rescued by miR-330-5p inhibition or MAPK1 overexpression. Collectively, our findings elucidate that circ_0071803 promotes CRC progression by regulating the miR-330-5p/MAPK1 pathway, providing potential therapeutic targets for designing effective targeted treatments.
Journal
|
MAPK1 (Mitogen-activated protein kinase 1) • MIR330 (MicroRNA 330)
|
MAPK1 overexpression
over3years
A functional role for Serum Amyloid A in the molecular regulation of autophagy in breast cancer. (PubMed, Front Oncol)
Lastly, SAA1/2 knockout promoted resistance to apoptosis and necrosis through the regulation of autophagy. SAA thus regulates autophagy in breast cancer cells to promote tumorigenesis.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • SAA1 (Serum Amyloid A1) • SQSTM1 (Sequestosome 1) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • MCM2 (Minichromosome maintenance complex component 2)
|
MAPK1 overexpression • SAA1 overexpression
over3years
MicroRNA-6838-5p suppresses the self-renewal and metastasis of human liver cancer stem cells through downregulating CBX4 expression and inactivating ERK signaling. (PubMed, Biol Chem)
Overexpression of miR-6838-5p suppressed Hep3B xenograft tumor growth in vivo, while CBX4 overexpression abrogated the suppression effect, restored the angiogenesis, epithelial-to-mesenchymal transition (EMT), and ERK signaling in Hep3B tumor. In summary, our findings suggest that miR-6838-5p/CBX4 axis regulates liver tumor development and metastasis, which could be utilized as potential therapeutic target for HCC treatment.
Journal
|
MAPK1 overexpression
over3years
TLR5 Variants Are Associated with the Risk for COPD and NSCLC Development, Better Overall Survival of the NSCLC Patients and Increased Chemosensitivity in the H1299 Cell Line. (PubMed, Biomedicines)
Finally, genome-wide transcriptomic analysis on WI-38 and H1299 cells overexpressing TLR5 or TLR5, respectively, indicated the existence of different transcription profiles affecting several cellular pathways potentially associated with a dysregulated immune response. Our results suggest that TLR5 could be recognized as a potential biomarker for COPD and LC development with functional relevance.
Preclinical • Journal • IO biomarker
|
TLR5 (Toll Like Receptor 5)
|
MAPK1 overexpression • TLR5 overexpression